GANX Gain Therapeutics Inc
Company Analysis
Latest News
🟢 Gain Therapeutics is trading 11% up — no clear catalyst identified
Gain Therapeutics is trading 10.84% higher at $1.32 on October 22, 2026, with no clear company-specific catalyst identified. - Company announcements surfaced...
🟢 Gain Therapeutics is trading 5.88% up on October 22, 2026 with no clear catalyst identified
Gain Therapeutics is trading at $1.26, up 5.88%, with no clear catalyst identified. - Its latest listed company announcements were dated October 8 and October...
🟢 Gain Therapeutics is trading 8% up in pre-market on October 20, 2026; catalyst remains unclear
Gain Therapeutics is trading at $1.35, up 8.00% in pre-market on October 20, 2026; the cause of the rise remains unclear. - No new company-specific...
🔴 Gain Therapeutics is trading 5% down today amid broad market and biotech weakness
Gain Therapeutics is trading 5.26% down now at $1.26, amid broad market and biotechnology weakness; no company-specific catalyst has been confirmed. - No...
🟢 Gain Therapeutics is trading 5% up in after-hours trading with no clear catalyst identified
Gain Therapeutics is trading 5.12% up at $1.39 in after-hours, with no clear company-specific catalyst identified. - Shares closed at $1.32 on October 14. The...
🔴 Gain Therapeutics is trading 5% down as broader risk-off sentiment may add pressure
Gain Therapeutics is trading 5.32% down at $1.33 on October 14, 2026, with no clear company-specific catalyst identified. - The previously announced Maxim...
🟢 Gain Therapeutics is trading 9.74% up in pre-market
Gain Therapeutics is trading at $1.55, up +9.74% in pre-market, with no clear company-specific catalyst identified. - The company’s previously announced Maxim...
🟢 Gain Therapeutics is trading 6.38% up in after-hours trading with no identified company-specific catalyst
Gain Therapeutics is trading 6.38% up in after-hours at $1.50, with no clear company-specific catalyst identified. - The regular session closed at $1.41 on...
🔴 Gain Therapeutics is trading 10% down amid biotech-sector weakness
Gain Therapeutics is trading at $1.41, down 10.18%, with no confirmed company-specific catalyst identified. - The supplied market context reports XBI down...
🔴 Gain Therapeutics is trading 5% down today amid broader biotech weakness
Gain Therapeutics is trading 5.1% lower now at $1.49, with broader biotech weakness providing context; no company-specific catalyst is confirmed. - XBI was...
Gain Therapeutics Reports 12-Month Stable Motor Scores in Parkinson’s Study
On October 1, 2026, Gain Therapeutics announced positive long-term data from the Phase 1b open-label extension study of rexaceract in patients with Parkinson’s...